Navigation Links
Nephros Reports Third Quarter 2013 Financial Results and Completes Bridge Financing
Date:11/14/2013

RIVER EDGE, N.J., Nov. 14, 2013 /PRNewswire/ -- Nephros, Inc. (OTC Bulletin Board: NEPH), a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, announced today financial results for the three and nine months ended September 30th 2013 and that the company entered into a bridge loan and security agreement with Lambda Investors LLC, an affiliate of Wexford Capital LP and the company's largest shareholder.

Financial Performance for the Third Quarter Ended September 30, 2013
Total net revenues for the three months ended September 30, 2013 were approximately $418,000 compared to approximately $604,000 for the three months ended September 30, 2012.  Total net revenues decreased by approximately $186,000, or 31%.  Overall, the key business segments of dialysis water and hospital water revenue increased by approximately $45,000 for the three months ended September 30, 2013.  There were no Military sales in the three months ended September 30, 2013 as compared with $114,000 of Military sales in the same period in 2012, in addition to which approximately $127,000 of anticipated sales credits are recorded to reflect the impact of a voluntary product recall of point of use filters (POU) announced on October 30, 2013. The overall product revenue decrease of $196,000, or 45%, is offset partially by an increase of approximately $10,000 as a result of increased licensing revenue related to the Bellco license agreement.

Total operating expenses for the quarter ended September 30, 2013 were $837,000 compared with $1,266,000 for the quarter ended September 30, 2012. The decrease was primarily driven by decreases in legal, accounting and professional services fees as well as personnel costs during the quarter ended September 30, 2013 compared to the quarter ended September
'/>"/>

SOURCE Nephros, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nephros Appoints John C. Houghton as President and Chief Executive Officer
2. Nephros Receives 510(k) Clearance for Hemodiafiltration System
3. Nephros Reports First Quarter 2012 Financial Results
4. Nephros Reports Second Quarter 2012 Financial Results
5. Nephros Reports Third Quarter 2012 Financial Results
6. Nephros and Chem-Aqua Announce Distribution Agreement
7. Nephros Completes Bridge Financing
8. Nephros Reports 2012 Fourth Quarter and Full Year Financial Results
9. Nephros Announces Rights Offering and Temporary Reduction in Exercise Price for March 2011 Warrants
10. Nephros Reports First Quarter 2013 Financial Results
11. Nephros Announces Completion of Rights Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
(Date:1/15/2014)... Mass. , Jan. 15, 2014  Zafgen, Inc., ... unmet needs of severely obese patients, today announced ... beloranib, a selective inhibitor of methionine aminopeptidase 2 ... severe form of genetic obesity.  These results showed ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
(Date:4/23/2014)... Fairfax, Va., April 23, 2014 The American Society ... guideline, "The Role of Postoperative Radiation Therapy for ... the use of adjuvant radiation therapy in the ... is published in the May-June 2014 issue of ... clinical practice journal of ASTRO. The full-length guideline ...
(Date:4/23/2014)... University researchers have developed a way to detect and ... tiny gold particles with tails of synthetic DNA., A ... biological engineering, used gold nanoparticles to target and bind ... RNA splice variants, which can indicate the presence and ... splice variants in a cell can be determined by ...
(Date:4/23/2014)... A novel compound that targets an important brain ... cocaine addiction behaviors, including relapse behavior, a University at ... strong evidence that this may be a novel lead ... medications exist., The UB research was published as an ... , In the study, the compound, RO5263397, severely blunted ...
(Date:4/23/2014)... 23, 2014Men whose testosterone falls below normal levels are ... overweight and have heart disease and type 2 diabetes. ... men for further testing and possible treatment is described ... , a peer-reviewed publication from Mary Ann Liebert, Inc., ... Journal of Men,s Health website at http://www.liebertpub.com/jmh ...
(Date:4/23/2014)... methods that can rapidly screen a large cell ... inside that population has been seriously lacking," said ... the Royal Society of Chemistry journal Chemical ... his coworkers have developed a novel technique that ... Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, http://pubs.rsc.org/en/content/articlelanding/2014/sc/c4sc00578c#!divAbstract ...
Breaking Medicine News(10 mins):Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2
... ACM Technology To Make Medical Pharmacy Claims Processing ... announced today the signing of,a new three-year contract ... it,easier for providers to submit claims for complex ... health plan. ACM,s proprietary,e-Precision claims(SM) technology will streamline ...
... 15 Althea Technologies, Inc., a leading,provider ... and manufacturing, announced today that E.J. Brandreth ... Quality and Regulatory. In this,role, Mr. Brandreth ... and,compliance programs, while overseeing the regulatory support ...
... recently held its 2008 Live Group Buy for Magnetic Resonance Imaging ... Hitachi Medical Systems America Inc. , ... Dallas, TX ... Group Buy for Magnetic Resonance Imaging (MRI), and Broadlane’s clients awarded ...
... Financial District Office Workers, Celebrities, Sports Personalities, and Corporate CEO's, are ... , ... San Francisco (PRWEB) July 15, 2008 -- ... United States has chosen Peacock Construction to bring his ...
... E-Prescribing Solution Can Help Organizations Achieve Benefits of H.R. 6331 ... ... Netsmart Technologies, Inc., a leading provider of enterprise-wide software and services ... special Web seminar to help behavioral health organizations understand e-prescribing ...
... ANGELES (STRICTLY EMBARGOED UNTIL JULY 15, 2008 AT 12:01 A.M. ... cell vaccine designed to fight malignant brain tumors called glioblastoma ... a patient,s immune response and clinical outcome, according to an ... Cancer Research . , While other studies have suggested a ...
Cached Medicine News:Health News:Blue Shield of California and ACM Sign New 3-Year Agreement 2Health News:Althea Technologies Appoints E.J. Brandreth to Vice President of Quality and Regulatory 2Health News:Broadlane's Live Group Buy Awards High-Field Open MRI Contract to Hitachi Medical Systems America Inc. 2Health News:Broadlane's Live Group Buy Awards High-Field Open MRI Contract to Hitachi Medical Systems America Inc. 3Health News:Broadlane's Live Group Buy Awards High-Field Open MRI Contract to Hitachi Medical Systems America Inc. 4Health News:Construction Begins on Executive Express Chiropractic at the SF Embarcadero Center 2Health News:Netsmart Technologies Web Seminar Helps Behavioral Health Organizations Understand Electronic Prescribing And The Importance Of New Medicare-Related E-Prescribing Legislation 2Health News:Netsmart Technologies Web Seminar Helps Behavioral Health Organizations Understand Electronic Prescribing And The Importance Of New Medicare-Related E-Prescribing Legislation 3Health News:Brain cancer study: Magnitude of post-vaccine immune response linked to clinical outcomes 2Health News:Brain cancer study: Magnitude of post-vaccine immune response linked to clinical outcomes 3
Part of the Octopus System which includes both the Starfish & Octopus3. The Starfish Heart Positioner simplifies cardiac positioning and minimizes the associated hemodynamic deterioration when compa...
... way to lift the heart - Guidant's ... 3. The XPOSE 3 is designed to ... surgery and to easily position and access ... both apical and non-apical placement on the ...
... Since its U.S. approval in 1992, ABIOMED's ... widely used advanced cardiac assist system in the ... only device approved by the U.S. Food and ... heart failure. ABIOMED continues to make advances ...
... The Arrow LionHeart Left Ventricular Assist ... is designed to be used as a ... end-stage (Class IV) congestive heart failure, for ... The Arrow LionHeart LVAS is not intended ...
Medicine Products: